16
ALL1
Allergan Aesthetics1
Boehringer Ingelheim GmbH2
Comera Life Sciences1
DSE Healthcare Solutions1
Famar1
Galt Pharmaceuticals2
Granules India Limited1
Nura Bio1
Seton Pharmaceuticals1
SkinMedica2
Strides Pharma Science2
Takeda PharmaceuticalYear
16
ALL2
20242
20234
20222
20216
2020DEALS // DEV.
16
ALL5
Deals11
DevelopmentsCountry
16
ALL1
GERMANY1
GREECE4
INDIA2
JAPAN8
U.S.A16
ALL2
Hypera Pharma2
LaviPharm10
Not Applicable1
Senores Pharmaceuticals1
The Column GroupTherapeutic Area
16
ALL2
Dermatology2
Immunology10
Neurology2
OncologyStudy Phase
16
ALL1
Approved FDF12
Approved1
Phase I2
PreclinicalDeal Type
5
ALL1
Acquisition1
Collaboration2
Divestment1
Series A FinancingProduct Type
16
ALL1
Large molecule1
Other Small Molecule14
Small moleculeDosage Form
14
ALL2
Capsule2
Cream2
Injectable/Injection1
Oral Tablet7
TabletLead Product
16
ALL4
Butalbital3
Caffeine2
Coffea Arabica1
Ipilimumab1
NB-47461
Orphenadrine4
ParacetamolTarget
6
ALL2
Adenosine receptor1
COX1/21
CTLA-42
GABA A receptorLead Product(s) : Paracetamol,Caffeine,Codeine Phosphate
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : LaviPharm
Deal Size : Undisclosed
Deal Type : Collaboration
FAMAR and Lavipharm Collaborate on Pharmaceutical Product Production
Details : Under the collaboration, FAMAR will produce two analgesic pharmaceutical products for Lavipharm: Lonarid N (paracetamol) and Lonalgal (caffeine anhydrous).
Product Name : Lonarid N
Product Type : Small molecule
Upfront Cash : Undisclosed
January 23, 2024
Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : LaviPharm
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Coffea Arabica,Caffeine,Hydrolyzed Rice Protein
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SkinMedica® Launches Even & Correct
Details : The SkinMedica (coffea arabica) Even & Correct products are hydroquinone-free, well tolerated, and effective on all skin types and for multiple ethnicities. Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product.
Product Name : SkinMedica
Product Type : Small molecule
Upfront Cash : Not Applicable
January 17, 2023
Lead Product(s) : Coffea Arabica,Caffeine,Hydrolyzed Rice Protein
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Paracetamol,Aspirin,Caffeine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Granules India Limited Announces Approval of Acetaminophen, Aspirin and Caffeine Tablets
Details : The US Food & Drug Administration (US FDA) has approved Abbreviated New Drug Application (ANDA) for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC).
Product Name : Acetaminophen/Aspirin/Caffeine-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
February 24, 2021
Lead Product(s) : Paracetamol,Aspirin,Caffeine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Butalbital,Paracetamol,Caffeine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Strides Receives USFDA Approval for Butalbital, Acetaminophen, and Caffeine Tablets
Details : Strides Pharma has received approval for Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325 mg/40 mg from the U.S Food & Drug Administration. The product is indicated for the relief of the symptom complex of tension (or muscle contraction) he...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
September 22, 2020
Lead Product(s) : Butalbital,Paracetamol,Caffeine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Butalbital,Paracetamol,Caffeine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : USFDA approved generic version of Butalbital, Acetaminophen, Caffeine with Codeine Phosphate Capsules which is indicated for the relief of the symptom complex of tension headache (migraine).
Product Name : Fioricet-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
July 09, 2020
Lead Product(s) : Butalbital,Paracetamol,Caffeine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Butalbital,Paracetamol,Caffeine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Granules India Limited Announces Approval of Butalbital, Acetaminophen and Caffeine
Details : USFDA approved generic version of Butalbital, Acetaminophen, Caffeine Capsules which is indicated for the relief of the symptom complex of tension headache (migraine).
Product Name : Butalbital-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
April 09, 2020
Lead Product(s) : Butalbital,Paracetamol,Caffeine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nura Bio Raises $68M Series A, Total Funds Exceed $140M
Details : The financing will support the clinical development of NB-4746, a SARM1 inhibitor currently being evaluated in early-stage trials for the treatment of amyotrophic lateral sclerosis.
Product Name : NB-4746
Product Type : Small molecule
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : LaviPharm
Deal Size : Undisclosed
Deal Type : Acquisition
Asset Purchase Agreement for Lavipharm
Details : Company acquires two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, used for fever and pain, for Greece and Cyprus markets with the intention to commercialize them internationally.
Product Name : Lonarid N
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 01, 2023
Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : LaviPharm
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Coffea Arabica,Caffeine,Hydrolyzed Rice Protein
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SkinMedica® Launches Firm & Tone Lotion for Body
Details : SkinMedica® Firm & Tone Lotion for Body is a luxurious formula rooted in science that delivers transformative results. It is clinically proven to diminish the look of crepey skin, address uneven skin texture, improve the appearance of skin and tone, and...
Product Name : SkinMedica
Product Type : Small molecule
Upfront Cash : Not Applicable
August 31, 2022
Lead Product(s) : Coffea Arabica,Caffeine,Hydrolyzed Rice Protein
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ipilimumab,Caffeine
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Comera announced favorable topline results of its SEQURUS-1 preclinical study in July, demonstrating supportive evidence of the safety of Comera’s lead caffeine-based proprietary SQore excipient when administered as a SQ biologic drug product formulati...
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Not Applicable
August 11, 2022
Lead Product(s) : Ipilimumab,Caffeine
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable